Intermittent Claudication Market Report 2025

The intermittent claudication market size has grown strongly in recent years. It will grow from $12.81 billion in 2024 to $13.64 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to factors such as the rise in peripheral artery disease, increased awareness of vascular diseases, growth in the geriatric population, higher diagnosis rates, and an increase in healthcare spending.

The intermittent claudication market size is expected to see strong growth in the next few years. It will grow to $17.39 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of diabetes, rising obesity rates, growing prevalence of cardiovascular diseases, higher alcohol and tobacco consumption, and increasing healthcare spending. Key trends in the forecast period include advancements in PAD diagnostics, the integration of wearable devices, the incorporation of personalized medicine, a shift toward drug-eluting stents, and progress in stem cell therapy.

The rising incidence of peripheral artery disease (PAD) is expected to drive the growth of the intermittent claudication market in the coming years. PAD is a circulatory condition where narrowed arteries reduce blood flow to the limbs, causing pain, numbness, and other complications. The increasing number of PAD cases is linked to factors such as an aging population, diabetes, smoking, hypertension, obesity, and sedentary lifestyles. PAD leads to intermittent claudication by limiting blood flow to the leg muscles during physical activity, resulting in pain and cramping due to a lack of oxygen. According to the American Heart Association Journals, published in June 2023, PAD affects 7 to 12 million people in the U.S. and 200 million people worldwide. This growing prevalence of PAD is driving the expansion of the intermittent claudication market.

Companies in the intermittent claudication market are focusing on developing advanced medication therapies, such as RIPK1 inhibitors, to improve treatment outcomes for patients with peripheral artery disease and intermittent claudication. These therapies aim to enhance blood flow, reduce inflammation, and prevent disease progression. RIPK1 inhibitors are targeted drugs that block RIPK1 kinase activity, which helps reduce inflammation and cell death. In August 2022, GenFleet, a biotechnology company based in China, received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial for GFH312, a new treatment for PAD with intermittent claudication. This randomized, double-blind, placebo-controlled study will take place at 15 research centers. GFH312 is a RIPK1 inhibitor that has shown promising results in preclinical studies by reducing inflammation in animal models.

In April 2023, Abbott Laboratories, a healthcare company based in the U.S., acquired Cardiovascular Systems Inc. for $890 million. This acquisition is aimed at expanding Abbott’s vascular device portfolio by incorporating Cardiovascular Systems Inc.'s advanced technologies for treating peripheral and coronary artery disease. The acquisition strengthens Abbott’s position in the cardiovascular market and improves patient care with innovative, minimally invasive solutions. Cardiovascular Systems Inc. is a U.S.-based medical device company known for its innovative treatments for peripheral artery disease, including intermittent claudication.

Major players in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, Pipelinepharma, Pharmaoffer, Alkem Laboratories, LGM Pharma, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma, and Pharmacompass.

North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intermittent claudication report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the intermittent claudication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Intermittent claudication is a condition marked by muscle pain, cramping, or discomfort in the legs that occurs during physical activity, such as walking, and is relieved by rest. It is usually caused by peripheral artery disease (PAD), which occurs when narrowed or blocked arteries restrict blood flow to the muscles. The pain is typically due to a lack of oxygen (ischemia) in the affected muscles.

The primary treatments for intermittent claudication include medication therapies and revascularization procedures. Medication therapies involve the use of drugs to relieve symptoms, improve blood flow, reduce pain, and prevent complications related to poor circulation. These medications are administered through various methods, such as parenteral, oral, and other routes, and are used in settings such as hospitals, clinics, and home healthcare. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The intermittent claudication market research report is one of a series of new reports that provides intermittent claudication market statistics, including the intermittent claudication industry's global market size, regional shares, competitors with a intermittent claudication market share, detailed intermittent claudication market segments, market trends and opportunities, and any further data you may need to thrive in the intermittent claudication industry. This intermittent claudication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The intermittent claudication market includes revenues earned by entities by providing services such as non-invasive tests, angioplasty, stent placement, supervised exercise therapy, and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The intermittent claudication market also consists of sales of antiplatelet agents, statins, vasodilators, and special socks or stockings. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.